333 related articles for article (PubMed ID: 35488519)
1. PRAME immunohistochemistry of spitzoid neoplasms.
Koh SS; Lau SK; Scapa JV; Cassarino DS
J Cutan Pathol; 2022 Aug; 49(8):709-716. PubMed ID: 35488519
[TBL] [Abstract][Full Text] [Related]
2. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
[TBL] [Abstract][Full Text] [Related]
3. PRAME Expression Correlates With Genomic Aberration and Malignant Diagnosis of Spitzoid Melanocytic Neoplasms.
Gerami P; Benton S; Zhao J; Zhang B; Lampley N; Roth A; Boutko A; Olivares S; Busam KJ
Am J Dermatopathol; 2022 Aug; 44(8):575-580. PubMed ID: 35503885
[TBL] [Abstract][Full Text] [Related]
4. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi.
Al Dhaybi R; Agoumi M; Gagné I; McCuaig C; Powell J; Kokta V
J Am Acad Dermatol; 2011 Aug; 65(2):357-363. PubMed ID: 21550132
[TBL] [Abstract][Full Text] [Related]
5. Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors.
Zaremba A; Jansen P; Murali R; Mayakonda A; Riedel A; Philip M; Rose C; Schaller J; Müller H; Kutzner H; Möller I; Stadtler N; Kretz J; Sucker A; Bankfalvi A; Livingstone E; Zimmer L; Horn S; Paschen A; Plass C; Schadendorf D; Hadaschik E; Lutsik P; Griewank K
Int J Cancer; 2022 Nov; 151(9):1542-1554. PubMed ID: 35737508
[TBL] [Abstract][Full Text] [Related]
6. Spitz Nevus and Other Spitzoid Tumors in Children -Part 1: Clinical, Histopathologic, and Immunohistochemical Features.
Sainz-Gaspar L; Sánchez-Bernal J; Noguera-Morel L; Hernández-Martín A; Colmenero I; Torrelo A
Actas Dermosifiliogr (Engl Ed); 2020 Jan; 111(1):7-19. PubMed ID: 31787210
[TBL] [Abstract][Full Text] [Related]
7. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma.
van Dijk MC; Bernsen MR; Ruiter DJ
Am J Surg Pathol; 2005 Sep; 29(9):1145-51. PubMed ID: 16096402
[TBL] [Abstract][Full Text] [Related]
8. The immunohistochemical profile of Spitz nevi and conventional (non-Spitzoid) melanomas: a baseline study.
Garrido-Ruiz MC; Requena L; Ortiz P; Pérez-Gómez B; Alonso SR; Peralto JL
Mod Pathol; 2010 Sep; 23(9):1215-24. PubMed ID: 20543820
[TBL] [Abstract][Full Text] [Related]
9. Expression of p16 alone does not differentiate between Spitz nevi and Spitzoid melanoma.
Mason A; Wititsuwannakul J; Klump VR; Lott J; Lazova R
J Cutan Pathol; 2012 Dec; 39(12):1062-74. PubMed ID: 23005921
[TBL] [Abstract][Full Text] [Related]
10. Expression of p15 in a spectrum of spitzoid melanocytic neoplasms.
Ma SA; O'Day CP; Dentchev T; Takeshita J; Ridky TW; Seykora JT; Chu EY
J Cutan Pathol; 2019 May; 46(5):310-316. PubMed ID: 30666677
[TBL] [Abstract][Full Text] [Related]
11. Utility of p16-Ki-67-HMB45 score in sorting benign from malignant Spitz tumors.
Garola R; Singh V
Pathol Res Pract; 2019 Oct; 215(10):152550. PubMed ID: 31351802
[TBL] [Abstract][Full Text] [Related]
12. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF; Oh KS; Alexis J
J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
[TBL] [Abstract][Full Text] [Related]
13. Atypical Spitz Tumors: A Diagnostic Challenge.
Harms KL; Lowe L; Fullen DR; Harms PW
Arch Pathol Lab Med; 2015 Oct; 139(10):1263-70. PubMed ID: 26414472
[TBL] [Abstract][Full Text] [Related]
14. Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions.
Harms PW; Hocker TL; Zhao L; Chan MP; Andea AA; Wang M; Harms KL; Wang ML; Carskadon S; Palanisamy N; Fullen DR
Hum Pathol; 2016 Dec; 58():152-160. PubMed ID: 27569296
[TBL] [Abstract][Full Text] [Related]
15. Spitz nevus and atypical spitzoid neoplasm.
Miteva M; Lazova R
Semin Cutan Med Surg; 2010 Sep; 29(3):165-73. PubMed ID: 21051010
[TBL] [Abstract][Full Text] [Related]
16. BRAF and NRAS mutations in spitzoid melanocytic lesions.
Fullen DR; Poynter JN; Lowe L; Su LD; Elder JT; Nair RP; Johnson TM; Gruber SB
Mod Pathol; 2006 Oct; 19(10):1324-32. PubMed ID: 16799476
[TBL] [Abstract][Full Text] [Related]
17. Combined utility of p16 and BRAF V600E in the evaluation of spitzoid tumors: Superiority to PRAME and correlation with FISH.
McAfee JL; Scarborough R; Jia XS; Azzato EM; Astbury C; Ronen S; Andea AA; Billings SD; Ko JS
J Cutan Pathol; 2023 Feb; 50(2):155-168. PubMed ID: 36261329
[TBL] [Abstract][Full Text] [Related]
18. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
Googe PB; Flanigan KL; Miedema JR
Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
[TBL] [Abstract][Full Text] [Related]
19. PRAME Expression in Challenging Dermal Melanocytic Neoplasms and Soft Tissue Tumors With Melanocytic Differentiation.
Kline N; Menge TD; Hrycaj SM; Andea AA; Patel RM; Harms PW; Chan MP; Bresler SC
Am J Dermatopathol; 2022 Jun; 44(6):404-410. PubMed ID: 34991102
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics associated with Spitz nevi and Spitzoid malignant melanomas: the Yale University Spitzoid Neoplasm Repository experience, 1991 to 2008.
Lott JP; Wititsuwannakul J; Lee JJ; Ariyan S; Narayan D; Kluger HH; Lazova R
J Am Acad Dermatol; 2014 Dec; 71(6):1077-82. PubMed ID: 25308882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
